Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

3,106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.
Tran B, Voskoboynik M, Bendell J, Gutierrez M, Lemech C, Day D, Frentzas S, Garrido-Laguna I, Standifer N, Wang F, Ferte C, Wang Y, Das M, Carneiro BA. Tran B, et al. Among authors: gutierrez m. Immunotherapy. 2024;16(11):759-774. doi: 10.1080/1750743X.2024.2359359. Epub 2024 Sep 12. Immunotherapy. 2024. PMID: 39264730 Free PMC article. Clinical Trial.
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Chénard-Poirier M, Hansen AR, Gutierrez ME, Rasco D, Xing Y, Chen LC, Zhou H, Webber AL, Freshwater T, Sharma MR. Chénard-Poirier M, et al. Among authors: gutierrez me. Invest New Drugs. 2024 Jun;42(3):241-251. doi: 10.1007/s10637-024-01428-0. Epub 2024 Mar 14. Invest New Drugs. 2024. PMID: 38483782 Free PMC article. Clinical Trial.
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
Puglisi M, Molife LR, de Jonge MJ, Khan KH, Doorn LV, Forster MD, Blanco M, Gutierrez M, Franklin C, Busman T, Yang J, Eskens FA. Puglisi M, et al. Among authors: gutierrez m. Future Oncol. 2021 Jul;17(21):2747-2758. doi: 10.2217/fon-2021-0140. Epub 2021 Apr 14. Future Oncol. 2021. PMID: 33849298 Free article. Clinical Trial.
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study.
Ku G, Haag GM, Park H, Lam VK, George TJ, Kim SS, Gutierrez M, Shankaran V, Stein S, Denlinger CS, Elimova E, Nagrial A, He AR, Sawyer MB, Yoon HH, Geva R, Starr J, Curigliano G, Golan T, von Moos R, Fritsch R, Lim D, Wang Q, Patel A, Aoyama T, Lei M, Greenawalt D, Di Bartolomeo M. Ku G, et al. Among authors: gutierrez m. ESMO Open. 2025 Jan 10;10(2):104107. doi: 10.1016/j.esmoop.2024.104107. Online ahead of print. ESMO Open. 2025. PMID: 39798422 Free article.
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies.
Saleh M, Barve M, Subbiah V, Papadopoulos KP, Morgensztern D, Mettu NB, Roychowdhury S, Spanggaard I, Veronese ML, Tian C, Silverman IM, Gutierrez M. Saleh M, et al. Among authors: gutierrez m. ESMO Open. 2024 Jul;9(7):103625. doi: 10.1016/j.esmoop.2024.103625. Epub 2024 Jul 9. ESMO Open. 2024. PMID: 38986210 Free PMC article. Clinical Trial.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Among authors: gutierrez m. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
3,106 results